Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Cambrex inks biologics pact

May 29, 2006 | A version of this story appeared in Volume 84, Issue 22

Cambrex's Bio Science Hopkinton subsidiary has landed a contract to produce clinical trial quantities of Merrimack Pharmaceuticals' MM-093, a recombinant version of human α-fetoprotein. The material will be used to assess MM-093's potential to treat autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and psoriasis. Phase II trials are under way for treatment of patients with rheumatoid arthritis or psoriasis. Cambrex says it has completed several batches of MM-093 with a process involving the purification of proteins expressed in transgenic goat's milk.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.